GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Item 9 Labs INLB · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Item 9 Labs — daily INLB Delayed
Market value
$9,569
Last close × shares
Volume
20k
Shares, 30 Oct 2026

About Item 9 Labs

Its shares trade under the ticker INLB. It has been listed since 3 November 2011. In the fiscal year to 30 September 2022, it reported revenue of $21.8m and a net loss of $31.1m. At that date it held total assets of $110.8m and shareholders' equity of $62.0m.

Item 9 Labs Corp. engages in creating cannabis health solutions for the modern consumer. The company is headquartered in Phoenix, Arizona. The company went IPO on 2011-11-03. The firm targets customers, such as compassionate sleeping partners, individuals with chronic sinus issues, individuals that suffer from chronic sleep disorders and individuals with allergies throughout the United States, Canada, Asia and Europe. The firm's products provide consumers with safe methods to control their own personal breathing environment. The firm's filtered product also contains 3M filtration media for allergy sufferers. The AIR nasal dilator is made from latex-free/adhesive-free hypoallergenic medical grade material. AIR nasal products are manufactured with or without 3M's Filtration Media depending on the whether the product is designed to enhance nasal breathing alone or in addition, filter the air of particulate matter, including allergens and bacteria.

Figures and description from our data supplier, not checked against the company's own report.

More about Item 9 Labs →

How it makes its money

Revenue, year to 30 Sept 2022

  • Corporate and Other [Member] $21.8m · 100.0%
  • Cultivation Segment [Member] $21.2m · 97.5%
  • Franchising Segment [Member] $395,713 · 1.8%
  • Corporate Segment [Member] $137,595 · 0.6%

Latest on Item 9 Labs

Our reporting

We have not reported on Item 9 Labs yet.

Next results

2 Dec 2026

Due on 2 Dec 2026. Analysts expect earnings of -0.04 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Item 9 Labs's ticker?

Item 9 Labs trades as INLB on its US listing, under ISIN US46564C2035.

What was Item 9 Labs's last closing price?

0.00 on 30 Oct 2026. The figure is in USD and is never converted.

When does Item 9 Labs next report results?

Results are expected on 2 Dec 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.